Physician profile
Sharmel Ormonde Kasten
NPI 1740365618
$4,712.91
in general payments reported to CMS, 2019-2025
36 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $511 · 2021: $12.60 · 2022: $377 · 2023: $669 · 2024: $1,083 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,134.12 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $856.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $429.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $255.55 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $225.12 | 2025 | Vowst, Zenpep |
| Amgen INC. | $195.43 | 2023-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $148.48 | 2024 | Ams 700 Cxr Rte Kit |
| Allergan, INC. | $144.16 | 2020 | |
| Glaxosmithkline, LLC. | $143.04 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $128.24 | 2019-2025 | |
| Madrigal Pharmaceuticals | $121.06 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $88.04 | 2024-2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $68.81 | 2023 | Ztlido, Elyxyb |
| Bayer Healthcare Pharmaceuticals INC. | $65.63 | 2022-2025 | |
| Abbott Laboratories | $64.11 | 2022-2025 | Freestyle Libre 3 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharmel Kasten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.